$ABBV earnings: guidance raise, and how the stock has historically moved after reports
AbbVie ($ABBV) reported Q1 adjusted EPS of $2.65 and raised its 2026 outlook on Skyrizi/Rinvoq strength.
How $ABBV has reacted to earnings
| Report | Next-day | 1-week |
|---|---|---|
| Jan 2025 | +4.7% | +9.9% |
| Apr 2025 | +3.2% | +7.2% |
| Oct 2025 | -4.5% | -4.0% |
| Feb 2026 | -3.8% | -1.4% |
| Apr 2026 | +3.1% | +4.3% |
Base rate (n=5):
- Median absolute next-day move: 3.8%
- Higher next day: 3 of 5
- Biggest up (next day): +4.7%
- Biggest down (next day): -4.5%
- Average 1-week move: +3.2%